We are live on ! Find out more
OMED

OncoMed Pharmaceuticals, Inc.
OMED

Delisted

OMED was delisted on the 22nd of April, 2019.

Back to rankings

Fund managers haven’t disclosed any holdings of OMED yet.

OMED Hedge Fund Activity: Q2 2019 in Review

0 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in OncoMed Pharmaceuticals, Inc. (OMED) for Q2 2019, worth a combined $0 — down 100% from $16.9M a quarter earlier.

Sellers outnumbered buyers: 41 funds closed out of OMED and 0 opened new positions — a net loss of 41 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Primecap Management, exiting entirely with an estimated $5.67M sold.

  • 0 institutional investors held OncoMed Pharmaceuticals, Inc. (OMED) as of Q2 2019, down from 41 in Q1 2019.
  • Funds reported $0 of OncoMed Pharmaceuticals, Inc. stock for Q2 2019, down 100% quarter-over-quarter.
  • 0 funds opened new OncoMed Pharmaceuticals, Inc. positions in Q2 2019 and 41 closed out, a net change of -41 holders.
  • The largest OncoMed Pharmaceuticals, Inc. seller in Q2 2019 was Primecap Management, an estimated $5.67M sold.

Based on aggregated 13F filings for Q2 2019.